Table 1.

Interpretation of pre‐treatment assessment in DAA candidates

Variable	Test	Interpretation
HCV genotype	Commercial assay using the sequence of the 5′untranslated region plus a portion of another genomic region, generally the core‐coding or the NS5B‐coding regions	Choose DAA regimen for specific HCV genotype following international guidelines
Disease stage	Transient elastography APRI: [{AST (IU/L)/AST_ULN (IU/L)} × 100]/ platelet count (109/L) FIB‐4: age (yr) × AST(IU/L)/platelet count (109/L × [ALT(IU/L)1/2] Liver biopsy	Cirrhosis: Plan surveillance schedule and assess complete liver function. Choose DAA regimen schedule based on fibrosis stage.
Liver function	Child‐Pugh‐Turcotte Score (Albumin, INR, Bilirubin, Ascites, encephalopathy)	CPT = A6 Prefer DAAs not including protease inhibitors. CPT >A6 Protease inhibitors must be avoided
Kidney function	Assess eGFR (Ckd‐Epi, Cockcroft‐Gault formula, MDRD)	eGFR <30 ml/min/m2 avoid sofosbuvir‐based regimens.
Concomitant medications	Assess comorbidities and concomitant medications (focus on immunosuppressant, cardiovascular and lipid‐lowering drugs). Warnings for PPIs and HIV medications	Check international guidelines and http://www.hep-druginteractions.org
HBV status	HBsAg, Anti‐HBs, Anti‐HBc. If HBsAg + check HBV DNA, HBeAg and anti‐HBeAg	HBsAg negative, anti‐HBc positive: Monitor and test for HBV reactivation in case of ALT elevation (check every 4 weeks). HbsAg‐positive patients fulfilling the standard criteria for HBV treatment should receive treatment following international guidelines. HBsAg‐positive patients not meeting HBV treatment criteria should be considered for concomitant nucleos(t)ide analogue prophylaxis until week 12 post DAA, and monitored closely.